Acella Pharmaceuticals Initiates Class II Recall for Doxycycline Hyclate Tablets Due to Dissolution Failure
Acella Pharmaceuticals, LLC has initiated a nationwide Class II recall for 4,680 bottles of Doxycycline Hyclate Tablets, USP 100 mg (Lot P24ZLK1) due to failed dissolution specifications. This voluntary action, reported on October 15, 2025, highlights critical quality control deficiencies impacting product efficacy. Procurement and regulatory teams must assess supply chain stability and identify alternative Doxycycline Hyclate sources to mitigate disruption and ensure patient access.
Recall Details: Acella Pharmaceuticals' Doxycycline Hyclate Dissolution Failure
Acella Pharmaceuticals, LLC has initiated a voluntary Class II recall, identified as D-0014-2026, for its Doxycycline Hyclate Tablets, USP 100 mg. This critical action stems from stability testing revealing that a specific lot, P24ZLK1, failed to meet established dissolution specifications. The affected product, distributed under NDC 42192-501-05 in 500-count bottles, has an expiration date of May 31, 2027. A total of 4,680 500-count bottles are subject to this nationwide recall across the USA. For procurement directors, this means an immediate assessment of existing inventory and purchase orders for this specific NDC is imperative. The failure to meet dissolution specifications implies that the drug may not release its active ingredient at the intended rate, potentially compromising the therapeutic efficacy of Doxycycline Hyclate, a widely used tetracycline antibiotic. Regulatory affairs heads must recognize that a Class II classification signifies a situation where the product could cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This event, initiated by Acella Pharmaceuticals on September 29, 2025, and reported to the FDA on October 15, 2025, underscores the critical importance of robust quality control throughout a drug product's lifecycle. Supply chain VPs should note the nationwide distribution, which necessitates broad communication and coordination with downstream partners to manage the recall effectively and minimize patient impact. Business development executives should evaluate the potential market perception shifts and competitive implications for generic Doxycycline Hyclate products.
Operational Impact: Acella Pharmaceuticals' Production and Distribution
Acella Pharmaceuticals, LLC operates from its facility located at 1880 Mcfarland Pkwy Ste 110, Alpharetta, Georgia, United States, with postal code 30005-1795. This site is the origin point for the Doxycycline Hyclate Tablets, USP 100 mg, involved in the current Class II recall. The nationwide distribution pattern of the affected Lot P24ZLK1 across the USA indicates that the product has reached a broad network of pharmacies, distributors, and healthcare providers, necessitating a comprehensive recall effort. For supply chain VPs, this incident originating from a US-based facility emphasizes that quality control vulnerabilities are not geographically confined, demanding consistent vigilance in supplier qualification and ongoing monitoring. Procurement teams must consider the implications of this recall on Acella's overall production capabilities and its future reliability as a supplier for ANDA210664. While specific details regarding the Alpharetta facility's broader production capacity or other products are not available, any increased regulatory scrutiny or operational adjustments at this site could impact the broader availability of Doxycycline Hyclate. Regulatory affairs teams should anticipate potential enhanced due diligence requirements for products associated with this facility, including future site audits or more stringent documentation requests, as the FDA assesses the firm's quality management systems. Business development executives should monitor any potential ripple effects on Acella's market standing and its ability to secure future contracts for its pharmaceutical portfolio.
Supply Chain Repercussions: Impact on Doxycycline Hyclate Procurement
The voluntary Class II recall of Acella Pharmaceuticals' Doxycycline Hyclate Tablets, USP 100 mg, directly impacts procurement strategies for this essential antibiotic. With 4,680 500-count bottles of Lot P24ZLK1 (NDC 42192-501-05) being removed from the market, companies that rely on Acella as a supplier face immediate supply continuity challenges. Procurement directors must urgently quantify their exposure to this specific lot and assess their remaining inventory of Doxycycline Hyclate from Acella to avoid stock-outs. This event necessitates a thorough review of existing supply contracts, with particular attention to clauses related to quality specifications, recall procedures, and liability. Furthermore, the disruption could lead to temporary price volatility or increased lead times for Doxycycline Hyclate across the US market, affecting downstream formulators, wholesalers, and healthcare providers. Regulatory affairs heads should advise on the implications for product registration and compliance, especially if their organizations distribute or reformulate products containing Doxycycline Hyclate sourced from Acella. Business development executives should evaluate opportunities arising from potential market gaps, while also considering the heightened scrutiny on generic drug quality. Ensuring uninterrupted patient access to Doxycycline Hyclate, a critical broad-spectrum antibiotic, becomes a paramount concern for the entire pharmaceutical supply chain, demanding proactive risk mitigation strategies.
Mitigating Risk: Identifying Alternative Doxycycline Hyclate Suppliers
In light of Acella Pharmaceuticals' Doxycycline Hyclate recall, procurement teams must prioritize the identification and qualification of alternative suppliers for Doxycycline Hyclate Tablets, USP 100 mg. Diversifying the supplier base is paramount to mitigate future supply chain disruptions and ensure consistent access to this critical antibiotic. Companies should immediately initiate searches for manufacturers holding approved Abbreviated New Drug Applications (ANDAs) for Doxycycline Hyclate, focusing on those with robust quality track records and sufficient production capacity to meet demand. Key considerations for procurement directors include the alternative supplier's regulatory history, facility inspection outcomes, and the availability of comprehensive stability data for their Doxycycline Hyclate products, particularly regarding dissolution profiles. Qualification timelines for a new pharmaceutical supplier can range from 6 to 18 months, encompassing rigorous audits, analytical testing, and potential regulatory filings, making proactive engagement critical. Regulatory affairs heads must ensure that any new supplier's product meets all FDA specifications for dissolution, bioavailability, and impurity profiles, aligning with ANDA requirements. Supply chain VPs should explore geographic diversification among suppliers to reduce geopolitical or regional manufacturing risks. While specific alternative suppliers are not detailed in our current intelligence, the market for generic Doxycycline Hyclate is competitive, offering several potential avenues for sourcing, though each requires thorough due diligence to ensure consistent quality and compliance, ultimately safeguarding patient access and business continuity.
Regulatory Context: Broader Implications for Pharmaceutical Quality
This Class II recall of Doxycycline Hyclate by Acella Pharmaceuticals, LLC, due to failed dissolution specifications, occurs within a broader landscape of heightened FDA scrutiny on pharmaceutical quality and manufacturing controls. While specific prior enforcement actions against Acella are not detailed in the available intelligence, this event aligns with a consistent FDA focus on ensuring generic drug products meet critical quality attributes, including dissolution, which directly impacts therapeutic performance and patient outcomes. Recent parallel events, such as Essential Wellness Pharma's progesterone injection failing sterility assurance, underscore the agency's vigilance across various product categories and quality parameters. For regulatory affairs heads, this signals a need for continuous internal audits and proactive remediation of any potential quality system gaps, particularly concerning stability testing and product release criteria. Procurement directors should factor a supplier’s overall quality culture and history of compliance into their vendor selection matrices, moving beyond just price considerations. Supply chain VPs must recognize that regulatory non-compliance, even if voluntary, can lead to significant market disruptions, increased operational costs, and reputational damage. This incident reinforces the industry-wide imperative for robust Quality Management Systems (QMS) to prevent such failures, maintain public trust in the pharmaceutical supply chain, and ensure the consistent delivery of safe and effective medicines.
Forward Outlook: Remediation and Market Stability
Following the voluntary Class II recall of Doxycycline Hyclate Tablets, USP 100 mg, Acella Pharmaceuticals, LLC is now responsible for executing a comprehensive recall strategy. This includes notifying all affected customers, ensuring proper segregation and disposition of the recalled Lot P24ZLK1, and providing clear instructions for return or destruction. Crucially, the firm must conduct a thorough investigation into the root cause of the dissolution failure and implement robust corrective and preventive actions (CAPAs) to prevent recurrence. For regulatory affairs heads, this involves preparing for potential FDA follow-up, which could include requests for detailed CAPA plans, evidence of their effective implementation, and potentially a re-inspection of the Alpharetta facility. The FDA will closely monitor the recall's effectiveness and assess Acella's remediation efforts. While the immediate market impact involves the removal of 4,680 bottles, the long-term stability of Doxycycline Hyclate supply from Acella will depend on the thoroughness and speed of their corrective actions. Procurement directors should maintain open communication with Acella regarding their remediation progress to gauge future supply reliability and inform long-term contracting decisions. Business development executives should monitor how this event influences market share dynamics for Doxycycline Hyclate, as competitors with strong quality records may gain an advantage. This incident serves as a reminder that even voluntary recalls can have lasting implications for a company's reputation and its ability to secure long-term supply contracts within the highly regulated pharmaceutical sector.